Consultation on the Prescription Drug List: Triamcinolone acetonide
Notice to the reader:
The online consultation is now closed.
The purpose of this Notice of Consultation is to provide an opportunity to comment on the proposal to revise the listing for Adrenocortical hormones on the Prescription Drug List (PDL). Only the human part of the PDL is proposed to be revised; the listing for Adrenocortical hormones for Veterinary use will remain unchanged.
A question-and-answer document has also been created to explain some of the changes to the new Prescription Drug List and the administrative process for assigning prescription status.
How to Get Involved
This consultation is open for comment until May 31, 2014. Please read through the information provided in the link below titled "Consultation Document". Once read, please submit your comments via email, facsimile or by mail to:
Health Canada
Prescription Drug Status Committee
Address Locator 3102C3
Holland Cross, Tower B
1600 Scott Street
Ottawa, Ontario
K1A 0K9
Telephone: 613-957-1058
Facsimile: 613-941-5035
E-mail: drug_prescription_status-statut_d'ordonnance_des_drogues@hc-sc.gc.ca
Interested parties are encouraged to provide comments and suggestions by May 31, 2014.
Reporting to Canadians
The results of the consultation will be made available on this website.
If you have any questions, contact us at the Prescription Drug Status Committee.